Notably, one large observational study demonstrated that even after adjusting for shared risk factors, such as stroke and other comorbidities, SGLT2 inhibitor use remained independently associated with a lower risk of both Alzheimer’s disease and vascular dementia [28]. The gene discussed is SLC5A2; the disease is early-onset autosomal dominant Alzheimer disease.